Ventana Biotech, Inc.
VNTA · OTC
12/31/2024 | 12/31/2023 | 12/31/2021 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.65 | 0.00 | 0.00 | -56.69 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 22.98 | 2,450.53 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 34.78% | 52.63% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.15 | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 2.29 | 3.85 | 0.00 | 0.00 |
| Interest Coverage | 630.15 | 0.00 | -0.09 | -0.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -33.97 | -3.44 | 0.00 | 0.00 |